Researchers developed HKC54, a selective TRPV2 antagonist that inhibits cancer cell migration in laboratory studies. This TRPV2 antagonist cancer cell migration research represents early-stage drug development that could eventually lead to new therapeutic approaches, though extensive additional testing is required before any clinical applications.